New developments in the diagnosis and treatment of thyroid cancer

DF Schneider, H Chen - CA: a cancer journal for clinicians, 2013 - Wiley Online Library
Answer questions and earn CME/CNE Thyroid cancer exists in several forms. Differentiated
thyroid cancers include those with papillary and follicular histologies. These tumors exist …

Heterogeneity of thyroid cancer

E Chmielik, D Rusinek, M Oczko-Wojciechowska… - Pathobiology, 2018 - karger.com
There are 5 main histological types of thyroid cancers (TCs): papillary, follicular (also known
as differentiated), poorly differentiated, anaplastic (the most aggressive form), and medullary …

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association …

DS Cooper, GM Doherty, BR Haugen, RT Kloos… - Thyroid, 2009 - liebertpub.com
Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the publication of the American Thyroid …

Guidelines for radioiodine therapy of differentiated thyroid cancer

M Luster, SE Clarke, M Dietlein, M Lassmann… - European journal of …, 2008 - Springer
Introduction The purpose of the present guidelines on the radioiodine therapy (RAIT) of
differentiated thyroid cancer (DTC) formulated by the European Association of Nuclear …

Thyroid papillary microcarcinoma: a descriptive and meta-analysis study

E Roti, EC degli Uberti, M Bondanelli… - European Journal of …, 2008 - academic.oup.com
The authors review anatomical, clinical characteristics and prevalence of thyroid
microcarcinoma. Diagnostic procedures and risk factors of aggressiveness at diagnosis and …

A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer

MS Brose, Y Panaseykin, B Konda… - The Journal of …, 2022 - academic.oup.com
Background Lenvatinib is a multikinase inhibitor approved to treat radioiodine-refractory
differentiated thyroid cancer (RR-DTC) at a starting dose of 24 mg/day. This study explored …

An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer

AM Sawka, JD Brierley, RW Tsang, L Thabane… - … and metabolism clinics …, 2008 - Elsevier
Radioactive iodine remnant ablation (RRA) is used to destroy residual normal thyroid tissue
after complete gross surgical resection of papillary or follicular thyroid cancer. The article …

Staging systems for papillary thyroid carcinoma: a review and comparison

BHH Lang, CY Lo, WF Chan, KY Lam… - Annals of surgery, 2007 - journals.lww.com
Objective: To find out the most predictive staging system for papillary thyroid carcinoma
(PTC) currently available in the literature. Background: Various staging systems or risk group …

Thyroid cancers: from surgery to current and future systemic therapies through their molecular identities

L Lorusso, V Cappagli, L Valerio, C Giani… - International Journal of …, 2021 - mdpi.com
Differentiated thyroid cancers (DTC) are commonly and successfully treated with total
thyroidectomy plus/minus radioiodine therapy (RAI). Medullary thyroid cancer (MTC) is only …

Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study

EN Klein Hesselink, MS Klein Hesselink… - Journal of Clinical …, 2013 - ascopubs.org
Purpose The primary aim was to study the risk of cardiovascular mortality in patients with
differentiated thyroid carcinoma (DTC). Secondary aims were to evaluate all-cause mortality …